6.14.2017
Various new data on Genentech’s Actemra (tocilizumab) and Rituxan (rituximab) will be presented at the 2017 European League Against… Continue Reading
6.14.2017
Leukodystrophies are inherited disorders of the white matter of the brain and spinal cord that can cause problems with movement, speaking,… Continue Reading
Castle Creek Announces First Patient Enrolled in DELIVERS Study of Diacerein 1% Ointment for Epidermolysis Bullosa Simplex
6.11.2017
Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic… Continue Reading
6.7.2017
CD Access is a new nonprofit that provides patients access to drugs and therapies that are currently unavailable through clinical trial… Continue Reading
Amicus Therapeutics Receives Rare Pediatric Disease Designation for SD-101 for Patients with Epidermolysis Bullosa
6.6.2017
Amicus Therapeutics, Inc.(link is external) (Nasdaq:FOLD), has received Rare Pediatric Disease designation from the U.S. Food and Drug… Continue Reading
ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10
6.5.2017
ProQR Therapeutics N.V.(Nasdaq:PRQR) today announced that it received Fast Track designation from the U.S. Food and Drug… Continue Reading
IPF Patients Treated with Ofev® VS Placebo Were Twice as Likely to Have Improved or Stable Lung Function
5.29.2017
Separate subgroup analysis demonstrates long-term efficacy of Ofev® in slowing disease progression is maintained for up to 96 weeks in IPF… Continue Reading
Talked About